Purchase this article with an account.
Bahram Bodaghi; Neoplastic routes to autoimmunity: Disease vs therapy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4406. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
It is generally accepted that all roads may lead to autoimmunity. Various ocular neoplastic conditions may masquerade as uveitis with diagnostic delay and sight or life-threatening complications. Different studies based on animal models but also affected patients have demonstrated cytokine profiles explaining disease pathophysiology, malignant tissue infiltration and secondary uveitis after efficient chemotherapy. More recently, immune-related ocular toxicities in solid tumor patients treated with biologic agents such as immune checkpoint or B-Raf inhibitors have emphasized a new challenging situation, which must be considered by oncologists and ophthalmologists involved in the care of these patients. Uveitis and dry eye syndrome are particularly important to consider in this particular setting. Direct action on neoplastic cells, alteration of the immune network or direct toxicity are potential mechanisms to consider. Temporary drug withdrawal and corticosteroids may control these immune-related ocular adverse events.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only